Corvus Pharmaceuticals: Durability, Not Peak Efficacy, Is The Real Product
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
Corvus: 'Strong Buy' On Continued Soquelitinib Advancement And HS Data 1st Half 2027
Corvus (CRVS) Q3 2026 Earnings Call Transcript
Corvus Pharmaceuticals Inc (CRVS) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Key ...
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2026 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
What Corvus Pharmaceuticals (CRVS) Said on Its Q3 Earnings Call
Corvus: Q3 Earnings Snapshot
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results
Corvus Pharma Q3 2026 Earnings Call Transcript
Corvus Pharma Q3 EPS $(0.22), Inline
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
Corvus Pharma Q2 2026 Earnings Call Transcript
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.